XTSXNSCI
Market cap25mUSD
Oct 21, Last price
1.32CAD
Name
Nanalysis Scientific Corp.
Chart & Performance
P/E
—
P/S
5.25
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.24%
Rev. gr., 5y
27.70%
Revenues
28m
+14.69%
Net income
-17m
L+69.28%
CFO
-11m
L+33.87%
Earnings
Apr 28, 2025
Profile
Nanalysis Scientific Corp., develops, manufactures, and sells compact nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging equipment for the pharmaceutical, biotech, chemical, security, food, materials, and education industries. It operates through three segments: Nanalysis, RS2D, and Corporate. The company also offers software module packages; manufactures and sells cutting-edge electronics components for precision analytical instruments; and provides monitoring and supporting services for its NMR technologies. It sells its products directly, as well as through a network of distributors worldwide. The company is headquartered in Calgary, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 28,466 14.69% | 24,821 54.72% | ||||||
Cost of revenue | 37,567 | 30,167 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (9,101) | (5,346) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (11) | (484) | ||||||
Tax Rate | ||||||||
NOPAT | (9,090) | (4,862) | ||||||
Net income | (16,784) 69.28% | (9,915) 321.38% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 25 | 266 | ||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 7,286 | 4,440 | ||||||
Long-term debt | 17,603 | 9,625 | ||||||
Deferred revenue | 1,117 | |||||||
Other long-term liabilities | 881 | 1,138 | ||||||
Net debt | 18,403 | 9,770 | ||||||
| Cash flow | ||||||||
Cash from operating activities | (11,185) | (8,355) | ||||||
CAPEX | (728) | (7,201) | ||||||
Cash from investing activities | (6,063) | (11,731) | ||||||
Cash from financing activities | 14,482 | 13,206 | ||||||
FCF | (7,884) | (14,202) | ||||||
| Balance | ||||||||
Cash | 759 | 3,525 | ||||||
Long term investments | 5,727 | 770 | ||||||
Excess cash | 5,063 | 3,054 | ||||||
Stockholders' equity | 18,808 | 43,634 | ||||||
Invested Capital | 41,267 | 57,526 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 99,176 | 92,476 | ||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (4,435) | (697) | ||||||
EV/EBITDA | ||||||||
Interest | 902 | |||||||
Interest/NOPBT | ||||||||